5-8 June, 2024
website
21-24 June, 2023
Poster presentation by Prof. Wong: “The effects of alfapump on ascites control and quality of life in patients with cirrhosis and recurrent or refractory ascites: Pivotal trial results”
download Poster
website
1-2 February, 2022
Presentation by Dr. Testani: “Direct Sodium Removal with the Sequana Medical alfapump DSR system”
download Presentation
website
July 15, 2021
“The Impact of Liver Ascites on Patients and Healthcare Systems and the potential of alfapump® therapy in NASH-related ascites”
Replay Webinar
Download presentation
29 June – 1 July, 2021
Presentation by Dr. Testani: “First in Human Experience with Alfapump DSR System in Diuretic Resistant Chronic Heart Failure”
download Presentation
website
11 December 2020
“The challenge of diuretic resistance in the management of heart failure patients and the potential for alfapump DSR therapy”
Replay webcast
Download presentation
2-5 October 2019, Wiesbaden, Germany
Presentation by Prof. Wong during lunch symposium on 4 October 2019: “Refractory Ascites: Reduce Fluid – Increase Quality of Life”
download
website
25-30 September 2019, San Francisco, US
Presentation by Dr. Testani on 28 September 2019: Direct Sodium Removal with an ambulatory peritoneal dialysis system
download
website
25-28 May 2019, Athens, Greece
Presentation by Dr. Testani during late-breaking session on 27 May 2019 (for webcast go to Investor Relations Events & Presentations page)
download
website
20-24 May 2019, Paris, France
Presentation by Ian Crosbie, CEO on 23 May 2019
download
website
9-13 November 2018, San Francisco
Poster session on 10 November 2018 by Dr. Florence Wong
download
website
14-16 September 2018, Kyoto, Japan
Poster session on 15 September by Prof. Dr. Christina Fotopoulou
download
website
15-18 September 2018, Tennessee
Poster session on 16 September by Dr. Jeffrey Testani
download
website
For Investor Relations Events & Presentations, please visit our Investors page.
GlobalData NASH Epidemiology Forecast to 2026
Testani JM, Hanberg JS, Cheng S, et al. Rapid and Highly Accurate Prediction of Poor Loop Diuretic Natriuretic Response in Patients With Heart Failure. Circulation Heart failure. 2016;9(1):e002370. doi:10.1161/CIRCHEARTFAILURE.115.002370
Kilgore et al. (2017); Ambrosy et al. (2014)
Ginès et al. (2004) (déclarant que l’ascite réfractaire apparaît chez 5 à 10% des patients souffrant d’ascite)
Runyon et al. (2009)
World Health Organization International Agency for Research on Cancer 2018 (website) (estimated number of new breast and ovarian cases in 2018 (crude rate))
Ayantunde et al. (2006)
Benjamin et al. (2013)
Costanzo et al. (2007)
Kilgore et al. (2017)
Estes et al. (2018)
European Association for the Study of the Liver. EASL clinical practice guideliones on the management of ascites, spontane bacterial peritonitis, and hepatorenal syndrome in cirrhosis. Journel of Hepatology. 2010 vol. 53. 397-417. p. 402
The alfapump® is still under clinical investigation in the US and Canada and therefore any statements regarding safety and efficacy do not apply in these territories.
The DSR therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
There is no link between the DSR therapy and ongoing investigations with the alfapump® system in Europe, the US and Canada.
U.S. Centers for Disease Control and Prevention, Health, United States 2016, Chartbook on Long-term trends in Health, Table 20 (web site)